cardiomyopathy

Indecainide (Ricainid) is a novel antiarrhythmic compound that is carcinogenic and can be used to study chronic stable ventricular arrhythmias secondary to coronary artery disease or cardiomyopathy.

JB062 is a chemical compound acting as a nonmuscle myosin inhibitor, exhibiting IC50 values of 1.6, 5.4, and >100 μM against skeletal muscle myosin, cardiac muscle myosin, and smooth muscle myosin II, respectively. It selectively exhibits cytotoxicity towards human cancer cells without affecting normal cells. The compound is applicable in research fields concerning muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.

Emprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene.

C2 Ceramide (d14:1/2:0) is a bioactive sphingolipid. Dietary administration of C2 ceramide (d14:1/2:0) (100 μM) induces lipotoxic cardiomyopathy via increasing diastolic and systolic diameter as well as reducing fractional shortening and the number of normal cardiac contractile events in Drosophila.

Vasomera, a stable, long-acting vasoactive intestinal peptide (VIP) agonist, targets G-protein-coupled VPAC2 receptors and is employed in the study of cardiomyopathy associated with dystrophinopathies [1].

FT011, a direct anti-fibrotic agent,attenuates cardiac remodelling and dysfunction in experimental diabetic cardiomyopathy.

Regaloside C is a glycerol glucoside isolated from Lilium genus with anti-inflammatory properties.

Visnagin has acute hypotensive, anti-inflammatory, and neuroprotective effects, it protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.

Moracin O shows significant neuroprotective, and analgesic activities, it also has a strong protective influence against doxorubicin-induced cardiomyopathy in H9c2 cells with the EC50 value of 4.5 ± 1.3 μM. Moracin O exhibits potent in vitro inhibitory ac

JB002, a myosin II inhibitor, exhibits potent activity with an IC50 of ≤10 μM. It holds potential for research applications in muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.

Aficamten is a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.

Ifetroban (BMS-180291) sodium is an orally active thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor antagonist. It is used to study myocardial ischaemia, stroke, hypertension, thrombosis and cardiomyopathy.

VO-OHPic is a reversible, noncompetitive, and selective inhibitor of PTEN with an IC50 of 46 nM. It effectively attenuates apoptosis, adverse cardiac remodeling, and the presence of pro-inflammatory M1 macrophages in models of doxorubicin-induced cardiomyopathy. Additionally, VO-OHPic inhibits autophagy [1] [2] [3].

CCG-273463 is a potent, covalent, selective inhibitor of GRK5 (IC50: 9 nM). CCG-273463 can be used to study heart failure, hypertrophic cardiomyopathy and cancer.

TUN-92046 (Dimethyl 2-oxoglutarate) is a membrane-permeable alpha-ketoglutarate analogue that inhibits maladaptive autophagy in pressure overloading induced cardiomyopathy.

Calhex 231 hydrochloride is a CaSR inhibitor with the potential for diabetic cardiomyopathy treatment. It blocks Ca2+-induced accumulation of [3H]inositol phosphate (IC50: 0.39 μM in HEK293 cells).

Cibenzoline is an antiarrhythmic agent that inhibits the KATP channel by directly affecting the pore-forming Kir6.2 subunit rather than the SUR1 subunit. Cibenzoline shows little anticholinergic activity. Cibenzoline markedly reduces LVPG which has a close relationship with myocardial contractility decreasing. Cibenzoline has the potential for hypertrophic obstructive cardiomyopathy research[1][2].

Derenofylline is a selective and potent adenosine A(1) antagonist in vitro (Ki=1 nM)